- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01195090
Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea (JAS)
Efficacy of Adding Sitagliptin or Pioglitazone to Patients With Type 2 Diabetes Insufficiently Controlled With Metformin and Sulfonylurea
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, open-label, randomized, parallel, 24-week study. Inclusion criteria: type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to their half maximally dose (sulfonylureas > half maximal dose, and metformin > 1500 mg/d) for > 10 weeks. > 20 years old; A1C:> 7.0 % and < 11% Exclusion criteria: insulin use within 12 weeks of the screening visit, any contraindications for use of sitagliptin or pioglitazone, impaired renal function (serum creatinine > 1.4 mg/dl), alanine aminotransferase (ALT) or aspartate aminotransferase levels (AST) > 2.5 times the upper limit of normal (ULN), current or prepare to pregnancy and lactation.
Primary Purpose:
compare the change in hemoglobin A1c and the proportion of patients achieving A1C < 7% between the 2 groups
Secondary Purposes:
- Changes in fasting plasma glucose, high sensitive C-reactive protein (hsCRP)
- Homeostasis model assessment-β cell function(HOMA-β) will be calculated to assess changes in β-cell function and HOMA-insulin resistance(HOMA-IR)to assess changes in insulin resistance
- Body weight change, proportion of side effects
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Taipei, Taiwan, 10449
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to their half maximally dose (sulfonylureas > half maximal dose, and metformin > 1500 mg/d) for > 10 weeks
- > 20 years old
- A1C: > 7.0 % and < 11%
Exclusion Criteria:
- Insulin use within 12 weeks of the screening visit
- Any contraindications for use of sitagliptin or pioglitazone, impaired renal function (serum creatinine > 1.4 mg/dl), alanine aminotransferase or aspartate aminotransferase levels > 2.5 times the upper limit of normal
- Current or prepare to pregnancy and lactation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: sitagliptin
add sitagliptin100mg/d to pre-study OADs
|
add sitagliptin100mg/d to pre-study OADs
Andre navn:
|
Aktiv komparator: pioglitazone
add pioglitazone 30mg/d to pre-study OADs
|
add pioglitazone 30mg/d to pre-study OADs
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Mean Change in Glycosylated Hemoglobin (A1C)
Tidsramme: 24 weeks
|
A1C change from baseline to 24 weeks
|
24 weeks
|
Baseline A1C
Tidsramme: Baseline
|
baseline A1C
|
Baseline
|
The Percentages of Patient Achieving an A1C <7%
Tidsramme: 24 weeks
|
The percentages of patient achieving an A1C <7% at endpoint
|
24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Changes in Fasting Plasma Glucose
Tidsramme: 24 weeks
|
fasting serum sugar change from baseline to 24 weeks
|
24 weeks
|
Changes in High Sensitive C-reactive Protein
Tidsramme: 24 weeks
|
fasting high sensitive serum C-reactive protein change from baseline to 24 weeks
|
24 weeks
|
Changes in Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Tidsramme: 24 weeks
|
HOMA-IR change from baseline to 24 weeks
|
24 weeks
|
Body Weight Change
Tidsramme: 24 weeks
|
body weight change from baseline to 24 weeks
|
24 weeks
|
Percentages of Patients With Total Adverse Events (AE)
Tidsramme: 24 weeks
|
percentages of total adverse events
|
24 weeks
|
Change in Fasting Total-cholesterol
Tidsramme: 24 weeks
|
Total-cholesterol change from baseline to 24 weeks
|
24 weeks
|
Change in Fasting Low-density Lipoprotein Cholesterol (LDL-C)
Tidsramme: 24 weeks
|
LDL-C change from baseline to 24 weeks
|
24 weeks
|
Change in Fasting Triglycerides(TG)
Tidsramme: 24 weeks
|
TG change from baseline to 24 weeks
|
24 weeks
|
Change in Fasting High-density Lipoprotein Cholesterol(HDL-C)
Tidsramme: 24 weeks
|
HDL-C change from baseline to 24 weeks
|
24 weeks
|
Change in Fasting Plasma Alanine-aminotransferase (ALT)
Tidsramme: 24 weeks
|
ALT change from baseline to 24 weeks
|
24 weeks
|
Percentages of Patients With Mild to Moderate Hypoglycemia
Tidsramme: 24 weeks
|
Incidence of mild to moderate hypoglycemia after treatment
|
24 weeks
|
Percentages of Patients With Edema
Tidsramme: 24 weeks
|
proportion of edema after treatment
|
24 weeks
|
Percentages of Patients With Gastrointestinal Adverse Events
Tidsramme: 24 weeks
|
Proportion of Gastrointestinal adverse events after treatment
|
24 weeks
|
Percentages of Patients With Nasopharyngitis
Tidsramme: 24 weeks
|
Proportion of Nasopharyngitis after treatment
|
24 weeks
|
Percentages of Patients With Severe Hypoglycemia
Tidsramme: 24 weeks
|
Proportion of severe hypoglycemia after treatment
|
24 weeks
|
Baseline Fasting Plasma Glucose
Tidsramme: baseline
|
Baseline fasting plasma glucose
|
baseline
|
Baseline High Sensitive C-reactive Protein
Tidsramme: baseline
|
Baseline high sensitive C-reactive Protein
|
baseline
|
Baseline Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Tidsramme: Baseline HOMA-IR
|
Baseline HOMA-IR
|
Baseline HOMA-IR
|
Baseline Alanine-aminotransferase (ALT)
Tidsramme: Baseline
|
Baseline alanine-aminotransferase
|
Baseline
|
Baseline Body Weight
Tidsramme: Baseline
|
Baseline body weight
|
Baseline
|
Baseline Total Cholesterol
Tidsramme: Baseline
|
Baseline Total cholesterol
|
Baseline
|
Baseline Triglyceride (TG)
Tidsramme: Baseline
|
Baseline TG
|
Baseline
|
Baseline Low-density Lipoprotein Cholesterol (LDL-C)
Tidsramme: Baseline
|
Baseline LDL-C
|
Baseline
|
Baseline High-density Lipoprotein Cholesterol (HDL-C)
Tidsramme: Baseline
|
Baseline HDL-C
|
Baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Sung-Chen Liu, MD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Glukosemetabolismeforstyrrelser
- Metabolske sykdommer
- Sykdommer i det endokrine systemet
- Sukkersyke
- Diabetes mellitus, type 2
- Hypoglykemiske midler
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Proteasehemmere
- Inkretiner
- Dipeptidyl-Peptidase IV-hemmere
- Pioglitazon
- Sitagliptinfosfat
Andre studie-ID-numre
- 09MMHIS047
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkjentHER-2 genamplifikasjon | HER-2 Protein Overekspresjon
-
The University of Tennessee, KnoxvilleFullførtMattelærere (2.–8. klasse) | Mattestudenter (2.–8. klasse)Forente stater
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkjentSolid svulst | HER-2 genamplifikasjon | HER2 genmutasjon | HER-2 Protein OverekspresjonKina
-
PowderMedFullført
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionHar ikke rekruttert ennå
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Har ikke rekruttert ennå
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeAktiv, ikke rekrutterende
-
AIM Vaccine Co., Ltd.Hunan Provincial Center for Disease Control and PreventionFullført
-
Indiana UniversityFullførtSARS-CoV-2Forente stater
-
Peking UniversityCenters for Disease Control and Prevention, China; Beijing Pinggu District... og andre samarbeidspartnereFullført
Kliniske studier på Sitagliptin
-
Shahid Beheshti University of Medical SciencesIsfahan University of Medical SciencesFullførtTrauma Patients in ICUIran, den islamske republikken
-
Emory UniversityMerck Sharp & Dohme LLCAvsluttet
-
University Hospital Inselspital, BerneFresenius KabiFullførtUnderernæring | Gastrointestinale svulsterSveits
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtType 1 diabetesForente stater
-
Lundquist Institute for Biomedical Innovation at...Emmaus Medical, Inc.Avsluttet
-
University of ArkansasUniversity Hospital, Geneva; Université de MontréalAvsluttetHepatisk encefalopati | Skrumplever | Ildfast ascites | Hepatisk HydrothoraxForente stater, Canada, Sveits
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.FullførtType 2 diabetes mellitusKina
-
Merck Sharp & Dohme LLCFullført
-
Merck Sharp & Dohme LLCFullført